Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results


Longer follow-up results from using the first coformulated injectable ART were presented from the phase 2b LATTE study. [1]

Following a lead period that included using oral formulations of cabotegravir and rilpivirine, 286 treatment-naive participants were randomised (2:2:1) to either 8-weekly (8W) or 4-weekly (4W) injections, or to oral cabotegravir plus abacavir/3TC.

Approximate baseline characteristics have been previously described and include 92% men, 80% white, CD4 489 cells/mm3 with 18% of participants having viral load >100,000 copies/mL.